GLP-1 Medications Compared: Wegovy, Ozempic, Zepbound, and Mounjaro Safety Guide (14 page pdf)

GLP-1 Medications Compared: Wegovy, Ozempic, Zepbound, and Mounjaro Safety Guide

Obesity affects 650 million adults worldwide, and semaglutide and tirzepatide have emerged as leading medications to curb this growing health crisis. The World Obesity Federation projects this number will reach one billion by 2030. Their data suggests that 51% of the global population will be overweight by 2035.

Research comparing tirzepatide and semaglutide for weight loss shows tirzepatide delivers substantially better results. Patients lost 4.23% more weight with tirzepatide than with semaglutide. Higher tirzepatide doses (>10 mg) showed even better results, with patients losing 6.50% more weight compared to semaglutide. Both medications share similar side effects, especially when it comes to gastrointestinal problems. These include nausea, vomiting, diarrhea, and pancreatitis. The key difference between these medications lies in how they work. Semaglutide acts as a GLP-1 receptor agonist, while tirzepatide works as a dual agonist for both GLP-1 and GIP receptors.

This piece explores the FDA approval timeline, effectiveness comparisons, side effect profiles, and ground evidence of these medications. You'll learn which option might work best for different patient groups.